A B S T R A C T Prostaglandin E2 (PGE2) infusion in normal humans inhibited acute insulin responses to a glucose (5 g i.v.) pulse (response before PGE2 = 593 + 104%; during PGE2 = 312+55%, mean+SE, mean change 3-5 min insulin, % basal, P < 0.005). This effect was associated with a decrease in glucose disappearance rates (KG before PGE2= 0.73+0.07; during PGE2= 0.49+0.06 %/min, P < 0.025). Acute insulin responses to arginine (2 g i.v.) were not affected by PGE2 (response before PGE2 = 592+164%; during PGE2 = 590+118%; P = NS). Infusion of sodium salicylate (SS), an inhibitor ofendogenous prostaglandin synthesis, augmented acute insulin responses to glucose in normals (response before SS = 313+62%; during SS = 660+86%; P < 0.001). In adult-onset diabetes with fasting hyperglycemia, SS restored absent acute insulin responses to glucose (20 g i.v.) pulses (response before SS = 5+6%; during SS = 97+24%; P < 0.005). This was accompanied by a fourfold augmentation in second phase insulin secretion (second phase before SS = 1,696+430%; during SS = 5,176±682%; change 10-60 min insulin, A min, % basal, P < 0.001) and by acceleration ml of glucose disappearance rates (KG before SS = 0.56 ±0.06; during SS = 1.02+0.17 %/min, P < 0.005). These findings uniquely demonstrate that (a) PGE2 inhibits glucose-induced acute insulin responses and decreases glucose disposal in nondiabetic humans and (b) SS restores acute insulin responses, augments second phase insulin secretion, and accelerates glucose disposal in hyperglycemic, adultonset diabetics. It is hypothesized that endogenous
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INTRODUCTION
Adult-onset diabetic patients with fasting hyperglycemia lack acute insulin responses (first phase insulin secretion) to glucose (1) . This abnormality in pancreatic B-cell function appears to be related specifically to glucose since acute insulin responses are present to a variety of other secretogogues, such as isoproterenol, amino acids, secretin, and glucagon (2) (3) (4) (5) . Elucidation of the underlying mechanism which causes defective acute insulin responses is important not only because this response is consistently absent in adult-onset diabetes mellitus, but also because the acute response is normally a major determinant of intravenous glucose tolerance (6) .
Lack of acute responses to glucose stimulation could be due to a defect within ,the pancreatic B cell or suppression of its normal function by endogenous factors. Consequently, considerable interest has developed in endogenous substances that can inhibit acute insulin responses. The only endogenous substances which have been demonstrated to be inhibitory in normal humans are catecholamines and somatostatin (7) (8) (9) (10) . We have previously reported that prostaglandins of the E series inhibit glucose-induced secretion in vivo in dogs (11, 12) . Unlike catecholamines and somatostatin, however, inhibition by prostaglandin E of insulin secretion is not reversed by a-adrenergic blockade (11, 13 25, 30, 45, 60, 90 , and 120 min after the intravenous pulses had been given. The 90-and 120-min samples were omitted after the 5-g glucose pulse.
Basal insulin levels were calculated as the mean of the four samples drawn before the first pulse. The acute insulin response (mean 3-5 min change insulin, % basal) was calculated as the mean of the 3-, 4-, and 5-min post-glucose injection values for a given subject from which was subtracted the insulin level immediately before the pulse for that subject; this number was then expressed as a percentage of the basal value. Second phase insulin secretion was calculated as the insulin area from 10 to 60 min after the 20-g pulse which was above the insulin level immediately before the pulse. This area was expressed as a percentage of the basal insulin level. Glucose disappearance rates (KG) were calculated as the slope of the regression line describing the inverse relationship between sampling times (10 to 30 min) and the natural logarithm of plasma glucose concentration and were expressed as percent per minute. After collection in EDTA, blood samples for glucose and insulin were kept at 40C until the end of the study and then centrifuged at 2,500 rpm and 4°C. The plasma was frozen for future analysis for glucose by an AutoAnalyzerferricyanide method (15) and for insulin by a modification of the method of Morgan and Lazarow (16) . Additional samples of blood were allowed to clot and the serum was measured for salicylate levels (17) . Statistical comparisons were performed by Student's t, paired t, and Wilcoxon rank-sum tests.
RESULTS
The effect of PGE2 infusions in normal subjects upon basal levels of insulin and glucose and their responses to intravenous glucose or arginine pulses. All normal subjects had fasting plasma glucose levels less than 112 mgldl. All subjects had acute insulin responses after 5 g of intravenous glucose (Fig. 1) ; base-line levels were reestablished by 60 min after the pulse. During the first 30 min of a subsequent PGE2 infusion, there was no change in the mean insulin level. After the second glucose pulse, an acute insulin response was observed; however, this response was significantly less than the response to the first glucose pulse (first response = 593+104%; second response = 312+55%; mean change 3-5 min insulin, % basal; mean+SE, n = 10, P < 0.005). In control studies which were identical except that saline rather than PGE2 was infused (Fig. 2) insulin response to a glucose pulse in the group of normal subjects receiving a sodium salicylate infusion was significantly greater than the response to a glucose pulse before the infusion (Fig. 4 ; first response = 313+62%; second response = 660+86%; n = 6, P < 0.001). Compared to preinfusion levels, sodium salicylate itself caused an increase in circulating insulin before the glucose pulse (preinfusion level = 115+17; 60 min after onset of infusion = 196+26 % basal, P < 0.01). There was a small but statistically insignificant increase in the mean glucose disappearance rate after the second glucose pulse compared to that after the first (Table I ; first pulse KG= 0.78 +0.11; second pulse KG= 0.89+0.14 %/min, P = NS).
The effect of sodium salicylate infusion in adultonset diabetics upon basal levels of insulin and glucose and their responses to intravenous glucose. The mean fasting plasma glucose level of the diabetic subjects receiving sodium salicylate was 196±19 mg/dl (Table II) . There was no mean acute insulin response to 20 g of intravenous glucose in this group of subjects ( Fig. 5 ; response = 5±+-6%, n = 12, P = NS). In contrast, after 60 min of sodium salicylate infusion, a second glucose pulse elicited acute insulin responses (response = 97+24%, P < 0.005). In addition, second phase insulin secretion was augmented (second phase after first pulse = +430%; after second pulse = 5,176+682%; change 10-60 min insulin, *. min, % basal; P < 0.001).
ml
Compared to preinfusion levels, sodium salicylate infusion itself caused an increase in circulating insulin (preinfusion level = 125+7; 60-min level = 231±21 % basal, P < 0.001). The control patients receiving saline rather than sodium salicylate infusion (Table II) had a mean fasting plasma glucose level of 231±29 mg/dl which was not significantly different from the group receiving sodium salicylate. This group also failed to have an acute insulin response after the first glucose pulse ( Fig. 5 ; response = -13+7%, n = 6, P = NS). In contrast to the patients receiving sodium salicylate, however, this group did not have acute insulin responses to the second glucose pulse (response= 11±10%, P= NS).
No augmentation of second phase insulin secretion was observed (second phase after first pulse= 1,137 + 562%; after second pulse = 1,950+915%; P = NS). Glucose disappearance rates (KG), acute insulin responses the first and second pulses (20 g i.v.) are compared.
infusion. In 12 of 12 diabetics, there was on the average a fourfold increase in second phase insulin secretion. The salicylate infusion itself caused a significant rise in circulating insulin before the glucose pulse. Glucose levels at this time in both normal and diabetic patients were not rising. None of these effects were observed in the control studies when saline rather than salicylate was infused in the normal and diabetic groups. Glucose disappearance rates decreased during PGE2 infusion in normals. There was significant acceleration of these rates in diabetics receiving salicylate inftision. Four of the diabetics reached rates which were within the normal range (>1.0%/min). No changes in rates were observed in the normal and diabetic control groups receiving saline rather than salicylate inftisions. The fact that the mean increase in rate was not statistically significant in the normal group receiving salicylate may indicate that a maximal rate for a 5-g glucose pulse had already been reached.
The inhibition of acute insulin responses and de- terioration of glucose disposal caused by PGE2 infusion is in agreement with previous in vivo nonhuman investigation (11) (12) (13) . The fact that PGE2 infusion did not lower basal insulin levels may be a doserelated phenomenon. Decreases in basal insulin levels were observed in our previously reported experiments in dogs given a PGE2 infuision rate of 10 ,sg/min (11, 12 
